Release Date: January 7, 2026
Expiration Date: January 7, 2027
Activity Overview
This educational activity is an archive of the live presentation held on December 5, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NPs/PAs, pharmacists, and other HCPs involved in the diagnosis and treatment of MPNs
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data for new and emerging strategies to treat patients with MPNs
- Determine appropriate evidence-based treatment for patients with newly diagnosed and previously treated MPNs
- Discuss considerations for the supportive care of patients with MPNs
- Describe strategies to identify and manage toxicities associated with treatments for MPNs
Naveen Pemmaraju, MD
Professor, Department of Leukemia
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Executive Director, MDACC Cancer Network for Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie , BMS Consulting CTI BioPharma, GSK Consulting, Immunogen, INCYTE, JNJ, Karyopharm Menarini-Stemline Group , Morphosys , OPNA, Pacylex , Protagonist , Sobi Takeda. Grant/Research Funding: Sager Strong Foundation United States Department of Defense (DOD). Board of Directors/Management: Dan's House of Hope
Shannon Elf, PhD
Associate Professor
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
Disclosures: Grant/Research Funding: Incyte, Ajax Therapeutics, Paragon Therapeutics
Angela Fleischman, MD, PhD
Program Co-Leader, Systems, Pathways & Targets
Associate Professor, Division of Hematology/Oncology
University of California, Irvine, School of Medicine
Irvine, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Speakers Bureau - Pharmaessentia, GSK, Sobi, Consultant - IONIS, Geron
Bethan Psaila, MD
Professor of Haematology
Weatherall Institute of Molecular Medicine and Ludwig Institute
for Cancer Research
University of Oxford
Oxford, England
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Incyte, GSK, BMS, Blueprint Medicines, Alethio Therapeutics, Novatris. Grant/ Research Funding: Incyte, Alethio Therapeutics Executive Role: Board Member - Alethio Therapeutics
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here